BMRNBioMarin Pharmaceutical Inc.

$12B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$538M+19.5% YoY

Gross Profit

$410M76.3% margin

Operating Income

-$25M-4.6% margin

Net Income

-$249,000-0.0% margin

EPS (Diluted)

$-0.00

QoQ Revenue Growth

+6.4%

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

-$30M

Stock-Based Comp.

$47M

Balance Sheet

Total Assets

$6.4B

Total Liabilities

$1.8B

Stockholders' Equity

$4.6B

Cash & Equivalents

$725M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$538M	$450M	+19.5%
Gross Profit	$410M	$330M	+24.3%
Operating Income	-$25M	-$66M	+62.8%
Net Income	-$249,000	-$58M	+99.6%

Revenue Segments

Product

$525M98%

Royalty And Other

$12M2%

BMRN Q4 2022 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena